Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K35/76

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/140012LYOPHILIZED VIRUS FORMULATIONS
WO 02.07.2020
Int.Class A61K 9/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
19lyophilised
Appl.No PCT/US2019/068700 Applicant AMGEN INC. Inventor FLOOD, Enrique, Alexander
Provided herein is a powder comprising a live, attenuated virus, recombinant human serum albumin (rHSA), a sugar other than lactose, a sugar alcohol, a source of phosphate, a source of chloride, wherein the composition is substantially free of lactose, gelatin, antibiotic, and free amino acids. In exemplary aspects, the powder is a lyophilizate of a liquid composition. Related liquid compositions, methods of preparing an oncolytic virus for administration and methods of treating melanoma are also provided herein.
2.WO/2020/135390ONCOLYTIC VIRUS EXPRESSING INTERFERON AND APPLICATION THEREFOR
WO 02.07.2020
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2019/127782 Applicant SHANGHAI YUANSONG BIOTECHNOLOGY CO. LTD. Inventor ZHANG, Kangjian
Provided is an oncolytic virus expressing an interferon. Specifically provided is an oncolytic adenovirus expressing an interferon hybrid protein, said oncolytic virus being capable of effectively suppressing tumors in vitro and in vivo.
3.WO/2020/135083USE OF CHEMOKINE RECEPTOR CXCR5
WO 02.07.2020
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2019/124916 Applicant GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD Inventor LI, Guangchao
The present disclosure provides use of chemokine receptor CXCR5, wherein CAR-T cells with enhanced chemotaxis are obtained by modifying chimeric antigen receptor T cells (CAR-T cells) utilizing the chemotactic signal between CXCR5 and its ligand CXCL13. The chemokine receptor CXCR5 can guide CAR-T cells to migrate to tumors.
4.WO/2020/139978CONJUGATED VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTI-TUMOR IMMUNE REDIRECTORS
WO 02.07.2020
Int.Class A61K 9/107
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions
Appl.No PCT/US2019/068619 Applicant VERIMMUNE LLC Inventor WANG, Joshua Weiyuan
Disclosed is a new class of conjugated virus-like particles (VLPs), These conjugated VLPs bind a wide variety of tumors and comprise epitopes recognized by a prior T cell immune response already existing in a host. These epitopes are derived from pathogens or previous vaccinations (such as early childhood vaccines). This provokes the body's pre-existing cytotoxic immunity obtained through previous infection or previous childhood vaccination to be redirected to the tumor cells for tire elimination of cancer, and form long-term anti-tumor immunity. The described conjugated VLPs are useful for tailoring a broad range of tumors towards a response from existing immunity circumventing the need to identify tumor antigens or generate tumor-specific immune responses, importantly, the compositions and methods described herein broadens opportunities for treatment for ail cancer types in subjects who previously had un-targetable cancers due to various technological and biological limitations of currently available immuno-therapeutic drugs.
5.20200199542MODIFIED ONCOLYTIC VIRUS
US 25.06.2020
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 16799090 Applicant Replimune Limited Inventor Robert S. Coffin

The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene.

6.WO/2020/127552TREATMENT OF CANCER HARBORING MUTATIONS IN THE TP53 GENE AND/OR POST- TRANSLATIONAL MODIFICATIONS IN THE P53 PROTEIN WITH PARVOVIRUSES
WO 25.06.2020
Int.Class A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Appl.No PCT/EP2019/086048 Applicant UNIVERSIDAD AUTÓNOMA DE MADRID Inventor ALMENDRAL DEL RÍO, José María
Treatment of cancer harboring mutations in the TP53 gene and/or post-translational modifications in the p53 protein. The present invention relates to the use of viruses belonging to the family Parvoviridae, genus Protoparvovirus, or combinations of such viruses with chemotherapy drugs, in the treatment of cancer. In particular the cancer is characterized by showing mutations in the TP53 gene and/or post-translational modifications in the p53 protein.
7.WO/2020/124273MODIFIED ORTHOPOXVIRUS VECTORS
WO 25.06.2020
Int.Class C12N 15/863
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
863Poxviral vectors, e.g. vaccinia virus
Appl.No PCT/CA2019/051898 Applicant OTTAWA HOSPITAL RESEARCH INSTITUTE Inventor BELL, John C.
The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.
8.WO/2020/124274MODIFIED ORTHOPOXVIRUS VECTORS
WO 25.06.2020
Int.Class C12N 15/863
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
863Poxviral vectors, e.g. vaccinia virus
Appl.No PCT/CA2019/051899 Applicant OTTAWA HOSPITAL RESEARCH INSTITUTE Inventor BELL, John C.
The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.
9.20200199624RECOMBINANT ONCOLYTIC VIRUS
US 25.06.2020
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No 16614441 Applicant Georgia State University Research Foundation, Inc. Inventor Ming Luo

Recombinant viral vectors are disclosed that contain a nucleic acid encoding a Second Mitochondria-derived Activator of Caspases (Smac) protein inserted within an RNA virus genome, wherein the Smac protein specifically binds to at least a portion of an Inhibitor of Apoptosis Protein (IAP). Also disclosed are methods of treating cancer using the disclosed vectors.

10.WO/2020/128012METHODS OF INDUCING AN IMMUNE RESPONSE
WO 25.06.2020
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/EP2019/086747 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor TOUSSAINT, Jean-Francois
There is provided inter alia a method of treating cancer in a mammal, said method comprising the steps of: (i) administering to the mammal a first composition comprising an antigen or comprising a nucleic acid encoding an antigen and (ii) administering to the mammal a second composition comprising an oncolytic virus wherein the oncolytic virus comprises a nucleic acid encoding the antigen.